Enzyvant Logo White Verticle

Patient Focused. Results Driven.

OUR MISSION

DEVELOP

Transformative therapies for rare diseases with high unmet needs.

PURSUE

Innovative partnerships that create new opportunities in the rare disease field.

DELIVER

On our commitment to the patients, families, and communities we serve.

OUR PIPELINE

RVT-802

Pediatric congenital athymia

Children with congenital athymia are generally born without a thymus, resulting in severe immunodeficiency due to the inability to produce normally functioning T cells, which defend against infection and regulate essential processes in the immune system. Left untreated, congenital athymia is fatal, typically within the first 24 months of life.

RVT-801

Acid ceramidase deficiency manifesting as Farber disease

Acid ceramidase deficiency is a devastating lysosomal storage disease caused by a mutation in both alleles of the ASAH1 gene, resulting in the deficiency of the lysosomal enzyme acid ceramidase.

November 1, 2019

Under a definitive agreement signed yesterday, DSP will acquire Roivant’s ownership interest in Enzyvant and four other Roivant companies with promising pipelines.

October 16, 2019

Enzyvant, a biopharmaceutical company focused on developing and commercializing transformative therapies for patients with rare, life-threatening conditions, today announced the appointment of Jeb Ledell as Chief Operating Officer.

June 5, 2019

Enzyvant today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its Biologics License Application (BLA) for RVT-802, a novel investigational tissue-based regenerative therapy designed to treat pediatric congenital athymia, and granted Priority Review.

Contact us for more information.